Biology subjects

Eisenhauer, P.

Publications and source records attributed to Eisenhauer, P..

4 recordsLinked to original sources

bioRxiv2026

Novel approaches to quantify defective interfering particle activity reveal a surrogate marker of interference in mammarenaviruses

Defective interfering particles (DIPs) profoundly influence viral replication and host responses yet it remains difficult to quantify their activity routinely in the laboratory. Here, using lymphocytic choriomeningitis virus (LCMV) as a model mammarenavirus, we establish complementary approaches for measuring interfering activity of DIPs across a range of experimental scales. First, we optimized plaque- and focus-based interference assays that directly quantify DIP-mediated suppression of standard infectious virus replication through a modified neutralization assay. Second, in cell monolayers saturated with both DIPs and infectious particles, we identified a complete loss of expression of the viral glycoprotein and matrix protein, which are each encoded in the positive-sense orientation of the mammarenavirus genome. Notably, this loss of protein expression mirrors the inhibition of plaque formation traditionally seen in this high DIP setting. The observed DIP-mediated loss of glycoprotein expression is a surrogate marker of interference and was used to develop an alternative assay of DIP activity. This glycoprotein expression assay recapitulated interference detected in traditional high-titer plaque assays (i.e. loss of plaques when all cells are saturated with DIPs and infectious particles) while substantially increasing scalability. These approaches enable sensitive and scalable quantification of DIP activity for LCMV as well as Junin virus and expand our experimental toolkit for studying arenavirus population dynamics, pathogenesis and immunity, and may help advance DIP-based antiviral strategies. This study also provides mechanistic details on how mammarenavirus DIPs interfere with infectious virus propagation.

microbiology↗

bioRxiv2026

Development and validation of two economical and flexible immunoassays for detecting antibodies against LCMV in mouse serum

Measurement of antibody responses to viral infection is essential for surveillance, diagnostics, epidemiological research, and natural history of infection studies. However, current methods to detect virus-specific antibodies are often resource-intensive and impractical for deployment in outbreak settings or in field-based studies. This manuscript presents two economical, high-throughput immunoassays--the cytoblot immunoassay (CBA) and strip immunoblot assay (SIA)--for detecting and quantifying anti-lymphocytic choriomeningitis mammarenavirus (LCMV) antibodies in mouse serum. To validate, we tested serum from acutely or persistently experimentally infected mice. Both assays detected LCMV-specific IgG and IgM antibodies with high sensitivity and specificity across multiple timepoints. By facilitating the study of immune responses in rodent reservoirs, these tools can enhance our understanding of zoonotic viral transmission, provide scalable platforms for outbreak preparedness, and serve as adaptable models for the development of rapid serological assays for other viral pathogens.

microbiology↗

bioRxiv2023

An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV

The capacity of SARS-CoV-2 to evolve poses challenges to conventional prevention and treatment options such as vaccination and monoclonal antibodies, as they rely on viral receptor binding domain (RBD) sequences from previous strains. Additionally, animal CoVs, especially those of the SARS family, are now appreciated as a constant pandemic threat. We present here a new antiviral approach featuring inhalation delivery of a recombinant viral trap composed of ten copies of angiotensin-converting enzyme 2 (ACE2) fused to the IgM Fc. This ACE2 decamer viral trap is designed to inhibit SARS-CoV-2 entry function, regardless of viral RBD sequence variations as shown by its high neutralization potency against all known SARS-CoV-2 variants, including Omicron BQ.1, BQ.1.1, XBB.1 and XBB.1.5. In addition, it demonstrates potency against SARS-CoV-1, human NL63, as well as bat and pangolin CoVs. The multivalent trap is effective in both prophylactic and therapeutic settings since a single intranasal dosing confers protection in human ACE2 transgenic mice against viral challenges. Lastly, this molecule is stable at ambient temperature for more than twelve weeks and can sustain physical stress from aerosolization. These results demonstrate the potential of a decameric ACE2 viral trap as an inhalation solution for ACE2-dependent coronaviruses of current and future pandemic concerns.

microbiology↗

bioRxiv2021

A global map of the Zika virus phosphoproteome reveals host-driven regulation of viral budding

Flaviviruses are enveloped, positive-strand RNA viruses that cause millions of infections in the human population annually. Although Zika virus (ZIKV) had been detected in humans as early as the 1950s, its reemergence in South America in 2015 resulted in a global health crisis. While flaviviruses encode 10 proteins that can be post-translationally modified by host enzymes, little is known regarding post-translational modifications (PTMs) of the flavivirus proteome. We used mass spectrometry to comprehensively identify host-driven PTMs on the ZIKV proteome. This approach allowed us to identify 43 PTMs across 8 ZIKV proteins, including several that are highly conserved within the Flavivirus genus. Notably, we found two phosphosites on the ZIKV envelope protein that are functionally important for viral propagation. Both appear to regulate viral budding, while one also impacts ZIKV cytopathogenicity. Additionally, we discovered host kinases that interact with ZIKV proteins and determined that Bosutinib--an FDA-approved tyrosine kinase inhibitor that targets some of these host kinases--impairs ZIKV growth, in part by blocking phosphorylation of a tyrosine residue on the envelope protein. Thus, we have defined a high-resolution map of host-driven PTMs on ZIKV proteins as well as cellular interacting kinases, uncovered novel mechanisms of host driven-regulation of ZIKV budding and cytopathogenicity, and identified an FDA-approved inhibitor of ZIKV growth.

microbiology↗